173 related articles for article (PubMed ID: 21083028)
1. Immunotherapy with histamine dihydrochloride for the prevention of relapse in acute myeloid leukemia.
Martner A; Thorén FB; Aurelius J; Söderholm J; Brune M; Hellstrand K
Expert Rev Hematol; 2010 Aug; 3(4):381-91. PubMed ID: 21083028
[TBL] [Abstract][Full Text] [Related]
2. Histamine dihydrochloride and low-dose interleukin-2 as post-consolidation immunotherapy in acute myeloid leukemia.
Thorén FB; Romero AI; Brune M; Hellstrand K
Expert Opin Biol Ther; 2009 Sep; 9(9):1217-23. PubMed ID: 19653866
[TBL] [Abstract][Full Text] [Related]
3. Post-consolidation immunotherapy with histamine dihydrochloride and interleukin-2 in AML.
Romero AI; Thorén FB; Aurelius J; Askarieh G; Brune M; Hellstrand K
Scand J Immunol; 2009 Sep; 70(3):194-205. PubMed ID: 19703009
[TBL] [Abstract][Full Text] [Related]
4. Role of regulatory T cells in acute myeloid leukemia patients undergoing relapse-preventive immunotherapy.
Sander FE; Nilsson M; Rydström A; Aurelius J; Riise RE; Movitz C; Bernson E; Kiffin R; Ståhlberg A; Brune M; Foà R; Hellstrand K; Thorén FB; Martner A
Cancer Immunol Immunother; 2017 Nov; 66(11):1473-1484. PubMed ID: 28721449
[TBL] [Abstract][Full Text] [Related]
5. Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial.
Brune M; Castaigne S; Catalano J; Gehlsen K; Ho AD; Hofmann WK; Hogge DE; Nilsson B; Or R; Romero AI; Rowe JM; Simonsson B; Spearing R; Stadtmauer EA; Szer J; Wallhult E; Hellstrand K
Blood; 2006 Jul; 108(1):88-96. PubMed ID: 16556892
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy with HDC/IL-2 may be clinically efficacious in acute myeloid leukemia of normal karyotype.
Nilsson MS; Hallner A; Brune M; Nilsson S; Thorén FB; Martner A; Hellstrand K
Hum Vaccin Immunother; 2020; 16(1):109-111. PubMed ID: 31242079
[TBL] [Abstract][Full Text] [Related]
7. Dynamics of myeloid cell populations during relapse-preventive immunotherapy in acute myeloid leukemia.
Rydström A; Hallner A; Aurelius J; Sander FE; Bernson E; Kiffin R; Thoren FB; Hellstrand K; Martner A
J Leukoc Biol; 2017 Aug; 102(2):467-474. PubMed ID: 28235771
[TBL] [Abstract][Full Text] [Related]
8. Addition of histamine to interleukin 2 treatment augments type 1 T-cell responses in patients with melanoma in vivo: immunologic results from a randomized clinical trial of interleukin 2 with or without histamine (MP 104).
Asemissen AM; Scheibenbogen C; Letsch A; Hellstrand K; Thorén F; Gehlsen K; Schmittel A; Thiel E; Keilholz U
Clin Cancer Res; 2005 Jan; 11(1):290-7. PubMed ID: 15671558
[TBL] [Abstract][Full Text] [Related]
9. Current and emerging therapies for acute myeloid leukemia.
Robak T; Wierzbowska A
Clin Ther; 2009; 31 Pt 2():2349-70. PubMed ID: 20110045
[TBL] [Abstract][Full Text] [Related]
10. A pilot study of interleukin-2 for adult patients with acute myelogenous leukemia in first complete remission.
Cortes JE; Kantarjian HM; O'Brien S; Giles F; Keating MJ; Freireich EJ; Estey EH
Cancer; 1999 Apr; 85(7):1506-13. PubMed ID: 10193940
[TBL] [Abstract][Full Text] [Related]
11. Histamine dihydrochloride: in the management of acute myeloid leukaemia.
Yang LP; Perry CM
Drugs; 2011 Jan; 71(1):109-22. PubMed ID: 21175244
[TBL] [Abstract][Full Text] [Related]
12. Histamine and interleukin-2 in acute myelogenous leukemia.
Hellstrand K; Mellqvist UH; Wallhult E; Carneskog J; Kimby E; Celsing F; Brune M
Leuk Lymphoma; 1997 Nov; 27(5-6):429-38. PubMed ID: 9477124
[TBL] [Abstract][Full Text] [Related]
13. Histamine dihydrochloride for the treatment of acute myeloid leukemia, malignant melanoma and renal cell carcinoma.
Perz JB; Ho AD
Future Oncol; 2008 Apr; 4(2):169-77. PubMed ID: 18407731
[TBL] [Abstract][Full Text] [Related]
14. Impact of IL-1β and the IL-1R antagonist on relapse risk and survival in AML patients undergoing immunotherapy for remission maintenance.
Grauers Wiktorin H; Aydin E; Christenson K; Issdisai N; Thorén FB; Hellstrand K; Martner A
Oncoimmunology; 2021; 10(1):1944538. PubMed ID: 34367728
[TBL] [Abstract][Full Text] [Related]
15. Histamine dihydrochloride and interleukin-2 in acute myeloid leukemia--background and results.
Brune M; Romero AI; Hellstrand K
Inflamm Res; 2009 Apr; 58 Suppl 1():4-8. PubMed ID: 19271134
[No Abstract] [Full Text] [Related]
16. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.
Büchner T; Hiddemann W; Berdel WE; Wörmann B; Schoch C; Fonatsch C; Löffler H; Haferlach T; Ludwig WD; Maschmeyer G; Staib P; Aul C; Gruneisen A; Lengfelder E; Frickhofen N; Kern W; Serve HL; Mesters RM; Sauerland MC; Heinecke A;
J Clin Oncol; 2003 Dec; 21(24):4496-504. PubMed ID: 14673036
[TBL] [Abstract][Full Text] [Related]
17. Spotlight on histamine dihydrochloride in acute myeloid leukaemia.
Yang LP; Perry CM
Drugs Aging; 2011 Apr; 28(4):325-9. PubMed ID: 21428467
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcomes of de novo acute myeloid leukemia in Thai patients.
Niparuck P; Chuncharunee S; Ungkanont A; Udomtrupayakul U; Aungchaisuksiri P; Rerkamnuatchoke B; Jootar S; Atichartakarn V
J Med Assoc Thai; 2009 Sep; 92(9):1143-9. PubMed ID: 19772172
[TBL] [Abstract][Full Text] [Related]
19. NK cell expression of natural cytotoxicity receptors may determine relapse risk in older AML patients undergoing immunotherapy for remission maintenance.
Martner A; Rydström A; Riise RE; Aurelius J; Brune M; Foà R; Hellstrand K; Thorén FB
Oncotarget; 2015 Dec; 6(40):42569-74. PubMed ID: 26544512
[TBL] [Abstract][Full Text] [Related]
20. Flow cytometric assessment of autologous gammadelta T cells in patients with acute myeloid leukemia: potential effector cells for immunotherapy?
Aswald JM; Wang XH; Aswald S; Lutynski A; Minden MD; Messner HA; Keating A
Cytometry B Clin Cytom; 2006 Nov; 70(6):379-90. PubMed ID: 16977635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
